Catalytically activating mutation in tyrosine kinase drives oncogenicity and drug resistance, but has unique weak points

Ryohei Katayama; Koutaroh Okada; Naoya Fujita

[4P-0542] Catalytically activating mutation in tyrosine kinase drives oncogenicity and drug resistance, but has unique weak points

〇Ryohei Katayama¹, Koutaroh Okada^1,2, Naoya Fujita^2,3 (1.Div. Experiment. Chemother., Cancer Chemother. Ctr., JFCR, 2.Dept. of CBMS., Grad. Sch. of Front. Sci., Univ. of Tokyo, 3.Cancer Chemother. Ctr., JFCR)

cancer, ALK, drug resistance

This archive has moved to the member page of The Molecular Biology Society of Japan.
Members can access the abstracts via links at the member page of the sites.
Please feel free to contact the journal offices for any inquiries.

The 42nd Annual Meeting of the Molecular Biology Society of Japan

[4P-0542] Catalytically activating mutation in tyrosine kinase drives oncogenicity and drug resistance, but has unique weak points

Password